María del Mar Noblejas‐López

Statistics

Publications

Citations

601

H-Index

Active since

2018

Affiliations

Centro de Investigación Biomédica en Red de Cáncer(Current)

University of Castilla-La Mancha

Hospital General Universitario de Albacete

Instituto de Investigación Biomédica de Salamanca

Centro de Investigación del Cáncer

María del Mar Noblejas‐López is an author at Centro de Investigación Biomédica en Red de Cáncer specializing in oncology, molecular oncology, and pharmacology.

ORCID

Publications per year

2018–2022

Publications

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

María del Mar Noblejas‐López, Cristina Nieto‐Jiménez, Miguel Burgos et al. · Journal of Experimental & Clinical Cancer Research · 2019 · 104 citations · Full text

Medicine, Oncology, Pharmacology +13

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer

Francisco J. Cimas, Enrique Niza, Alberto Juan et al. · Pharmaceutics · 2020 · 86 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome

María del Mar Noblejas‐López, Cristina Nieto‐Jiménez, Sara Morcillo García et al. · OncoImmunology · 2019 · 82 citations · Full text

Life Sciences, Immunology, Oncology +17

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer

Enrique Niza, María del Mar Noblejas‐López, Iván Bravo et al. · Nanomaterials · 2019 · 61 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy

Enrique Niza, Cristina Nieto‐Jiménez, María del Mar Noblejas‐López et al. · Nanomaterials · 2019 · 54 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

1–5 of 14